| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Maria Teresa Busceti | Q124854007 |
| Alessandro Vatrella | Q48541083 | ||
| Rosa Terracciano | Q55080364 | ||
| Girolamo Pelaia | Q87123110 | ||
| Corrado Pelaia | Q94456854 | ||
| P2093 | author name string | Nicola Lombardo | |
| Cecilia Calabrese | |||
| Eugenio Garofalo | |||
| P2860 | cites work | Role of biologics in severe eosinophilic asthma - focus on reslizumab | Q26738503 |
| Benralizumab: a unique IL-5 inhibitor for severe asthma | Q26750711 | ||
| Update on anticytokine treatment for asthma | Q27013617 | ||
| Structure of the activation domain of the GM-CSF/IL-3/IL-5 receptor common beta-chain bound to an antagonist | Q27622116 | ||
| A novel dimer configuration revealed by the crystal structure at 2.4 A resolution of human interleukin-5 | Q27732152 | ||
| Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs | Q28067081 | ||
| Management of the patient with eosinophilic asthma: a new era begins | Q28078191 | ||
| Eosinophilic Inflammation in Asthma | Q29031455 | ||
| Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity | Q30835165 | ||
| Eosinophil Activation Status in Separate Compartments and Association with Asthma | Q33785627 | ||
| Mechanisms of eosinophil-associated inflammation | Q33886210 | ||
| Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia | Q34230967 | ||
| Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma | Q34557028 | ||
| Mitogen-activated protein kinases and asthma | Q35865902 | ||
| The intracellular signal transduction mechanism of interleukin 5 in eosinophils: the involvement of lyn tyrosine kinase and the Ras-Raf-1-MEK-microtubule-associated protein kinase pathway | Q36364828 | ||
| Lyn, Jak2, and Raf-1 kinases are critical for the antiapoptotic effect of interleukin 5, whereas only Raf-1 kinase is essential for eosinophil activation and degranulation | Q36401490 | ||
| IL-3, IL-5, and GM-CSF signaling: crystal structure of the human beta-common receptor | Q36617062 | ||
| Benralizumab--a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma | Q36654007 | ||
| Current concepts of severe asthma | Q37042266 | ||
| IL-5 and eosinophilia. | Q37176808 | ||
| T-helper type 2-driven inflammation defines major subphenotypes of asthma. | Q37343774 | ||
| Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor | Q37957225 | ||
| The potential of biologics for the treatment of asthma | Q38063791 | ||
| Innate lymphoid cells--how did we miss them? | Q38071916 | ||
| Targeting eosinophils in allergy, inflammation and beyond | Q38075409 | ||
| Eosinophil resistance to glucocorticoid-induced apoptosis is mediated by the transcription factor NFIL3. | Q38417153 | ||
| Cellular mechanisms underlying eosinophilic and neutrophilic airway inflammation in asthma. | Q38423076 | ||
| Prevalence of eosinophilia in hospitalized patients with asthma exacerbation | Q38551793 | ||
| Interleukin-5 Inhibitors for Severe Asthma: Rationale and Future Outlook | Q38736845 | ||
| Efficacy and Safety of Benralizumab, a Monoclonal Antibody against IL-5Rα, in Uncontrolled Eosinophilic Asthma | Q38818964 | ||
| The clinical profile of benralizumab in the management of severe eosinophilic asthma | Q38822826 | ||
| Molecular and cellular mechanisms underlying the therapeutic effects of budesonide in asthma | Q38887287 | ||
| A randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthma | Q39090432 | ||
| New Anti-Eosinophil Drugs for Asthma and COPD: Targeting the Trait! | Q39352939 | ||
| Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial | Q39408906 | ||
| The Biology of Eosinophils and Their Role in Asthma | Q39438308 | ||
| T cell-replacing factor (TRF)/interleukin 5 (IL-5): molecular and functional properties | Q39640081 | ||
| Establishment of humanized anti-interleukin-5 receptor alpha chain monoclonal antibodies having a potent neutralizing activity | Q39845720 | ||
| Eosinophilic and Non-Eosinophilic Asthma. | Q40046428 | ||
| Allergic diseases: From bench to clinic - Contribution of the discovery of interleukin-5. | Q40061195 | ||
| Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial | Q40198084 | ||
| Interleukin-5 and its receptor system: implications in the immune system and inflammation. | Q40602176 | ||
| The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity | Q40690773 | ||
| The immunology of asthma | Q41673436 | ||
| Regulation of interleukin-5-induced beta2-integrin adhesion of human eosinophils by phosphoinositide 3-kinase | Q42066789 | ||
| Eosinophilic asthma: insights into the effects of reducing IL-5 receptor-positive cell levels | Q42825415 | ||
| Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma | Q43049820 | ||
| Sputum CD34+IL-5Ralpha+ cells increase after allergen: evidence for in situ eosinophilopoiesis | Q44663899 | ||
| Eosinophils in the spotlight: Eosinophilic airway inflammation in nonallergic asthma | Q44715380 | ||
| IL-5 and granulocyte-macrophage colony-stimulating factor activate STAT3 and STAT5 and promote Pim-1 and cyclin D3 protein expression in human eosinophils | Q45140680 | ||
| Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab | Q45676532 | ||
| Asthma and corticosteroids: time for a more precise approach to treatment | Q46072029 | ||
| Biological mechanisms underlying the clinical effects of allergen-specific immunotherapy in asthmatic children | Q47429419 | ||
| Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma | Q47555559 | ||
| Efficacy and safety of benralizumab in patients with eosinophilic asthma: a meta-analysis of randomized placebo-controlled trials | Q47686042 | ||
| Severe and Difficult-to-Treat Asthma in Adults | Q47848891 | ||
| Benralizumab attenuates airway eosinophilia in prednisone-dependent asthma | Q49572572 | ||
| Benralizumab: an anti-IL-5 receptor α monoclonal antibody in the treatment of asthma | Q49850833 | ||
| Important and specific role for basophils in acute allergic reactions | Q50065229 | ||
| Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma | Q50152491 | ||
| Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. | Q51026334 | ||
| A Phase 2a Study of Benralizumab for Patients with Eosinophilic Asthma in South Korea and Japan. | Q51531321 | ||
| Kinetic interaction analysis of human interleukin 5 receptor alpha mutants reveals a unique binding topology and charge distribution for cytokine recognition. | Q51598582 | ||
| Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia. | Q51611177 | ||
| Allergen-induced increases in bone marrow T lymphocytes and interleukin-5 expression in subjects with asthma. | Q51704000 | ||
| Reductions in eosinophil biomarkers by benralizumab in patients with asthma. | Q53641303 | ||
| Mucosal Inflammation and Asthma | Q59685309 | ||
| MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function | Q60632052 | ||
| The activation of the Jak-STAT 1 signaling pathway by IL-5 in eosinophils | Q71848076 | ||
| Enhancement of human eosinophil apoptosis by fluticasone propionate, budesonide, and beclomethasone | Q73098618 | ||
| ERK1 and ERK2 activation by chemotactic factors in human eosinophils is interleukin 5-dependent and contributes to leukotriene C(4) biosynthesis | Q73643163 | ||
| The differential role of extracellular signal-regulated kinases and p38 mitogen-activated protein kinase in eosinophil functions | Q74108345 | ||
| The mechanism of IL-5 signal transduction | Q77217607 | ||
| Asthma | Q89218803 | ||
| Asthma | Q89723811 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | asthma | Q35869 |
| globulins | Q321710 | ||
| monoclonal antibody | Q422248 | ||
| blood proteins | Q425056 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 4839230 | |
| P577 | publication date | 2018-05-10 | |
| P1433 | published in | BioMed Research International | Q17509958 |
| P1476 | title | Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma. | |
| P478 | volume | 2018 |
| Q89941328 | Effects of the first three doses of benralizumab on symptom control, lung function, blood eosinophils, oral corticosteroid intake, and nasal polyps in a patient with severe allergic asthma |
| Q64113098 | Efficacy and steroid-sparing effect of benralizumab: has it an advantage over its competitors? |
| Q92536062 | Interleukin-5 in the Pathophysiology of Severe Asthma |
| Q92504767 | Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis |
| Q58583982 | Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness |
| Q90333130 | Role of Biologics in Asthma |
| Q98772414 | The use of biologics in children with allergic rhinitis and chronic rhinosinusitis: Current updates |
Search more.